Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

July 17, 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the findings from the STORM trial, a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC).

July 16, 2014

Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation.

July 11, 2014

Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis that examined the detection of BRAF mutations in urine and plasma cell-free DNA in patients with Langerhans Cell Histiocytosis(LCH) and Erdheim-Chester Disease (ECD) who have a BRAFV600E mutation

July 10, 2014

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the idea of using combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

July 07, 2014

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.

June 30, 2014

Every patient with a rare but aggressive form of ovarian cancer had tumors with the same type of mutations, suggesting a causative role for the mutations.

June 04, 2014

A new independently validated lab test is now available that takes advantage of the extensive database of gene mutations amassed by Memorial Sloan Kettering (MSK) Cancer Center.

May 06, 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective analysis that evaluated embolization versus embolization plus systemic therapy in patients with metastatic hepatocellular carcinoma (HCC).

April 30, 2014

At the 18th Annual International Congress on Hematologic Malignancies, Anas Younes, MD, sat down with Oncology & Biotech News to discuss trends in the management of hematologic malignances.

April 25, 2014

Obesity increases the chance that someone will get the clear-cell form of renal cell carcinoma (ccRCC). But once an obese patient has the disease, he's likely to survive longer than a non-obese patient.

April 25, 2014

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.

April 21, 2014

A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression

April 18, 2014

Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.

February 25, 2014

During the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures

February 10, 2014

During his undergraduate years at Princeton University, Charles L. Sawyers, MD, studied history. Now, well into his career as a physician and translational scientist, Sawyers is busy making it.

February 07, 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.

January 30, 2014

Alison J. Moskowitz, MD, is among researchers at Memorial Sloan-Kettering Cancer Center and elsewhere who are investigating an expanded role for the CD30-targeting brentuximab vedotin (Adcetris) in hematologic malignancies. Moskowitz specializes in the treatment of patients with lymphoma and her research focuses on evaluating novel treatments for Hodgkin lymphoma.

January 29, 2014

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan-Kettering Cancer Center, discusses graft-versus-host disease (GVHD) and T cell depletion.

January 13, 2014

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses some of the challenges of treating patients with lung cancer.

January 10, 2014

Juliet N. Barker, MBSS, director, Cord Blood Transplantation Program, Memorial Sloan-Kettering Cancer Center, discusses using double-unit cord blood transplantation with a haplo-identical donor in patients with hematologic malignancies.